ABSTRACT BACKGROUND Both the modified History, Electrocardiogram, Age, Risk factors and Troponin (HEART) score and the
Patients presenting to EDs with chest pain have among the largest variations in hospital admission rates, but lack clearly associated differences in observed mortality (2, 3) . Much of the variation in practice is driven by low-grade recommendations to secure functional (exercise electrocardiography, nuclear stress testing, or stress echocardiography) or anatomic (coronary computed tomography angiography) testing in patients with possible acute coronary syndromes (ACS) before or within 72 h of hospital discharge (4, 5) . However, among those without diagnostic electrocardiograms (ECGs) and/or cardiac biomarkers, only 1% to 4% of these patients have angiographic evidence of significant coronary artery disease (6) (7) (8) .
Given the relatively low yield of this historic approach to possible ACS, researchers have created risk scores to identify patients at low risk of major adverse cardiac events (MACE). Among these, the modified History, Electrocardiogram, Age, Risk factors and Troponin (HEART) score and the Emergency Department Assessment of Chest pain Score (EDACS), both of which treat abnormal troponin values as independent, non-low-risk factors, stand out with the best specificities (ranging from 40% to 60%) in achieving negative predictive value (NPV) estimates >99% for 30-to 45-day MACE, specifically when applied alongside accelerated diagnostic protocols employing cardiac troponin I (cTnI) measurement at ED arrival and 2 to 3 h later (9) (10) (11) (12) . Used in this fashion, both scores have demonstrated improvements in operational efficiency and downstream resource utilization (10, 12) . A simplified unweighted version of the EDACS, which has minimal reliance on presenting symptoms, performs similarly well in terms of NPV, albeit with lower specificity (13) .
The use of these risk scores may allow for direct discharge of patients with possible ACS from the ED without further planned cardiac testing, an approach that appears safe, medico-legally acceptable to clinicians, and cost-effective (12, (14) (15) (16) (17) . However, adoption in practice is limited by imprecision in risk estimates, as well as uncertainty surrounding the optimal cTnI cutoff, given increased risks of future MACE among patients with cTnI concentrations at the high end of the normal range (18) (19) (20) (21) .
Accordingly, we sought to improve both the precision and accuracy of risk estimates by exploring the incorporation of alternative cutoffs for cTnI below the 99th percentile among a large retrospective cohort drawn from the electronic health record of an integrated health system. We contextualized our analysis and findings from a risk-benefit perspective using estimated testing thresholds for functional or anatomic testing in patients with possible ACS, supported by cost-benefit estimates (14, 22) . We hypothesized that improved accuracy and precision in risk estimates could identify a sizeable portion of ED patients with possible ACS for whom routine functional or anatomic testing is unlikely beneficial (8, (22) (23) (24) (25) . Table 1 ). Only the first qualifying visit for any given patient during the study period was included.
cTnI values at all sites were obtained using the Access AccuTnI assay (Beckman-Coulter, Brea, California) from the beginning of the study period through July 14, 2014, and then using the Access AccuTnIþ3 assay (Beckman-Coulter, Brea, California) from July 15, 2014, through the end of the study period. The 99th percentile for both assays is 0.04 ng/ml per local institutional reporting guidelines and reference published reports (26) . In terms of imprecision, the coefficient of variation at a concentration of 0.04 ng/ml is 14% and 10% for the Access AccuTnI and Access AccuTnIþ3, respectively; at 0.02 ng/ml, it is 20% for both assays, making 0.02 ng/ml the lowest acceptable cutoff value for the exclusion of myocardial infarction (limit of Comparing the EDACS and Modified HEART Score quantitation) (27) . The limits of blank and detection for both assays are <0.01 ng/ml and 0.01 ng/ml, respectively.
DATA COLLECTION AND OUTCOME MEASURES. To identify predictor variables for the risk score calculations ( Table 1) , we used a combination of electronic extraction of structured data (Online Table 2 Mark et al.
Comparing the EDACS and Modified HEART Score Table 3 .
RISK SCORE CALCULATION AND RESULT REPORTING. The modified HEART, original EDACS, and simplified EDACS scores were calculated for each eligible patient, assigning points as per Table 1 , with the history component of the modified HEART score calculated as described in the Online Appendix (12, 13) . We dichotomized each score into low-risk and non-low-risk categories using previously reported cutoffs, with non-low-risk designation indicated by a modified HEART score $4, an original EDACS $16 or a simplified EDACS $4 (9,12,13). We also further stratified populations based on the highest reported cTnI values (below the 99th percentile) during the ED evaluation. Finally, given published sex-and age-specific differences in the 99th percentile for cTnI, we also assessed stratification on these variables (26, 29) . Time-to-event curves were generated to compare MACE rates between identified risk strata. Analysis was performed using SAS version 9.3 (SAS institute, Cary, North Carolina).
Because, in terms of disposition decision making, ED physicians are primarily concerned with the posterior probability of disease among patients with undifferentiated chest pain, we reported test characteristics for the low-risk categories of each respective risk score in terms of either the NPV or outcome rate per 1,000 patients. We elected not to report sensitivity and specificity because we excluded patients with either cTnI concentrations above the 99th percentile or a MACE diagnosis in the ED, recognizing that the resulting lower overall acuity and prevalence of disease will result in lower test sensitivities and higher specificities (spectrum effect), potentially causing unnecessary confusion (30) .
RECLASSIFICATION YIELD. To quantitatively summarize differences in accuracy among the 3 risk scores, as well as between alternative cTnI thresholds, we reported the net increase in true positives (patients with a MACE reclassified as non-low risk) and the net increase in false positives (patients without a MACE reclassified as non-low risk) as a proportion (net increase in true positives over the sum of the net increase in both true and false positives), which we term the "reclassification yield."
This allows for an estimate of the event rate among the sum of patients reclassified as non-low risk, which can then be directly compared to a test threshold to determine whether the reclassification scheme was beneficial. We calculated test thresholds using the methods of Pauker and Kassirer (22) with risk-benefit estimates from the available published reports (8, (31) (32) (33) (34) (35) , resulting in testing threshold estimates between 0.71% and 0.91%, below which the risks of false-positive testing are outweighed by the potential for harm from untreated disease (36) . To simplify interpretation, we designated a reclassification yield of >1% as clinically significant. To alternatively contextualize these testing thresholds, we also extrapolated cost-effectiveness data (14) for exercise treadmill testing and computed tomography coronary angiography, which yielded cost estimates in excess of $100,000 per quality-adjusted life-year gained.
Details of these calculations are provided in the Online Appendix.
SENSITIVITY ANALYSES. We conducted 8 sensitivity analyses by altering the inclusion, exclusion, and outcome criteria for the cohort (Online Appendix).
These analyses were meant to provide a broader range of 60-day MACE and MACE plus estimates by removing certain assumptions (e.g., including patients with comorbid chest pain-related exclusion diagnoses), as well as to examine narrower populations (e.g., patients with 2 or more cTnI measurements in the ED).
RESULTS
From a total of 3,267,915 encounters within the 21 EDs of the Kaiser Permanente Northern California integrated health system during the study period, among those undergoing cTnI testing in the ED, there were a total of 172,304 adult patients (5.27%) who presented with a chief complaint of chest pain or chest discomfort, and a total of 112,691 patients (3.45%)
Comparing the EDACS and Modified HEART Score who were given a primary or second position ICDcoded diagnosis of chest pain by their ED physician, resulting in 188,310 (5.76%) unique patient encounters, of which 8.0% had a known 60-day MACE.
Exclusion criteria left a total of 118,822 patients with possible ACS for analysis in the study cohort. A CONSORT diagram of the cohort selection is presented in Figure 1 .
The demographic characteristics of the study cohort are presented in Table 2 . The median age was 59 years, 42.70% were male, and 9.88% were hospitalized at the index ED encounter. The overall 60-day MACE rate was 1.94%, whereas the overall 60-day MACE plus rate was 3.69%. Follow-up cardiac testing (functional or anatomic) was requested for 41.50% of all patients within the next 30 days.
Analysis stratified by varying cTnI cutoffs revealed a clinically significant reclassification yield (i.e., >1%)
only at the transition between a cTnI concentration of <0.02 ng/ml (lower limit of quantitation) and 0.02 ng/ml, a finding that persisted regardless of sex or age strata (Online Tables 4 and 5 ). When applied to the 3 risk scores, using a lower cTnI cutoff of <0.02 ng/ml, as compared with the 99th percentile (0.04 ng/ml), resulted in reclassification yields ranging from 3.40% to 3.93%, indicating clinically important improvements in accuracy (Table 3) . Table 4) .
Building upon these data, we conceptualized 4 strata of risk among patients with possible ACS by combining risk scores with dichotomized peak ED cTnI concentrations within the 99th percentile (<0.02 ng/ml vs. 0.02 to 0.04 ng/ml), graphically represented for each risk score with time-to-event MACE ( Figure 2 ) and MACE plus (Online Figure 1) 
FIGURE 1 Study Cohort Selection
• MACE diagnosis in ED (n = 5,400)
• MACE diagnosis in 30 days prior to ED visit (n = 2,874)
• Alternative non-ACS diagnoses at index ED visit or admission* (n = 29,472)
• No active health plan membership in month of the index ED visit and two months following, except in cases of death (n = 22,863)
• Troponin I result >0.04 ng/ml (n = 14,706)
Exclusions:
60-day MACE rate 1.9% 60-day MACE rate 8.0%
Primary study cohort (n = 118,822)
• Age ≥18 years
• Troponin I testing during ED visit
Initial cohort (n = 188,310) with either chief complaint of chest pain/discomfort (n = 172,304) or ICD-coded ED diagnosis of chest pain (n = 112,691), plus: Mark et al.
Comparing the EDACS and Modified HEART Score F E B R U A R Y 1 3 , 2 0 1 8 : 6 0 6 -1 6 survival curves. Overall, 8% to 9% of patients with a low-risk score and 21% to 25% with a non-low-risk score had peak cTnI concentration in the 0.02 to 0.04 ng/ml range while in the ED, which correlated with a roughly 5-fold increase in estimated 60-day MACE rates compared with the same risk score category with a peak cTnI concentration of <0.02 ng/ml.
When comparing accuracy between the 3 low-risk scores for predicting 60-day MACE using a cTnI cutoff of <0.02 ng/ml ( signifying that significant nonrandom bias in electronic risk score calculation was highly unlikely (Online Table 10 ).
DISCUSSION
In this retrospective study of patients with possible ACS following an ED evaluation, we found that the accuracy of a low-risk classification for 60-day MACE by 3 risk scores (modified HEART, original EDACS, and simplified EDACS) was optimized using a cTnI concentration threshold of <0.02 ng/ml (lower limit of quantitation) (Central Illustration). Of the 3 risk scores, the original EDACS classified the greatest proportion of patients as low risk and performed similarly when compared when either the modified HEART score or the simplified EDACS in terms of accuracy.
The fact that lowering the cTnI threshold for lowrisk designation below the 99th percentile resulted in a clinically significant reclassification yield is not surprising. Indeed, using the 99th percentile may be a misguided approach to excluding downstream MACE, because patients with varying levels of cardiac disease (and MACE risk) are unavoidably present in reference populations. As such, a strategy designed to "rule out" disease will require a lower determinant threshold as compared with a "rule-in" strategy. This phenomenon is evident in the fact that average cTn concentrations are lower than the 99th percentile among similarly aged patients with minimal rates of long-term cardiac outcomes (18, 20, 21) . Even for near-horizon events, studies examining the predictive value of high-sensitivity cTn in practice have shown that thresholds well below the 99th percentile and/or a lack of very small changes in cTn on serial testing offer improved NPV for 30-day MACE over use of the 99th percentile (37) (38) (39) . Other studies have demonstrated that adding clinical risk criteria can reasonably allow the use of the 99th percentile to exclude short-term outcomes (10, 12, 40, 41) . As such, a combination of the 2 strategies (use of a risk score with a cTn threshold below the 99th percentile) is likely to offer improved safety and discrimination for longer-term outcomes, as suggested by our findings.
Whether further improvements in accuracy can be obtained using lower cTn thresholds in conjunction with risk scores remains unclear, but offers an avenue for further exploration with high sensitivity cTn assays (42) . Regardless, it is arguable that the levels of NPV for 60-day MACE observed among the lowest risk group (low-risk score and cTnI <0.02 ng/ml) are sufficiently low to consider forgoing further evaluation with functional or anatomic cardiac testing. Indeed, several observational studies have found a lack of reduction in downstream MACE when pursuing such testing among similarly low risk patients (8, (23) (24) (25) . At the very least, this practice is not likely to be costeffective, with estimates in excess of $100,000 per quality-adjusted life-year when applied to populations with MACE rates below 1%, as summarized in the Online Appendix (14) .
Along these lines, in terms of optimizing resource utilization, the original EDACS may be the preferred single risk score because it classified the greatest proportion of patients as low risk. Two prospective and 2 retrospective validation studies of the original EDACS yielded similar low-risk proportions among ED patients with chest pain which, individually or pooled, also demonstrated NPVs for 30-day MACE (pooled 95% CI: 99.23% to 99.94%) that overlap the 95% CIs seen in our study, further supporting this conclusion (9) (10) (11) 43) . Tables 1 and 2 . It is also possible that our cohort selection method resulted in dilution of the sample with patients whose clinicians did not truly have concern for ACS (spectrum bias). To assess for this possibility, we restricted the analysis to patients with either 2 cTnI measurements in the ED (sensitivity analysis S2), or orders for functional or anatomic cardiac tests within 30 days (sensitivity analysis S8) as potential surrogate markers for higher clinical concern. We found that the MACE rates in both these groups were up to 2-fold lower than the primary cohort, arguing against such a bias. The lower MACE rate among the S2 group may be due to expedited hospital admission without serial cTnI testing in the ED among patients who later ruled in for ACS, as suggested by similar MACE rates in the S5 analysis, which excluded patients with a MACE within 1 day of hospital admission at the index visit.
At the same time, ED clinicians may have further selected out lower-risk patients through the use of serial cTnI testing. Together, these findings support Comparing the EDACS and Modified HEART Score recommendations to perform serial and/or appropriately delayed cTn testing in the ED, as was done in the modified HEART pathway and EDACS accelerated diagnostic protocol studies (9, 10, 12) .
It should also be noted that the 2 most recent studies of the EDACS added "red flag" criteria (crescendo angina or abnormal vital signs) as standalone, non-low-risk criteria, irrespective of the risk score, in order to reach NPV point estimates of 100% (10,11). Although we were unable to fully evaluate the impact of these additional criteria given limitations in assessing for crescendo angina retrospectively, we intentionally did not include vital signs in our primary validation analysis because these were not found to improve diagnostic accuracy in the derivation of the EDACS (9) . Regardless, the NPV estimates found in the lowest-risk group need not be 100% to justify forgoing further testing, as discussed in the preceding text.
CONCLUSIONS
Among ED patients with possible ACS, either the modified HEART score, the original EDACS or the simplified EDACS were accurate in predicting a low risk of 60-day MACE (i.e., >99% NPV), with the original EDACS classifying the greatest proportion of patients as low-risk. Accuracy was Tables 1 to 3 . Comparing the EDACS and Modified HEART Score
